Vyome (HIND) Competitors

$2.23 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.22 -0.02 (-0.67%)

As of 05/22/2026 07:58 PM Eastern

HIND vs. SRTS, ECOR, NSPR, NTRB, and PSTV

Should you buy Vyome stock or one of its competitors? MarketBeat compares Vyome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vyome include Sensus Healthcare (SRTS), electroCore (ECOR), InspireMD (NSPR), Nutriband (NTRB), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry.

How does Vyome compare to Sensus Healthcare?

Vyome (NASDAQ:HIND) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Sensus Healthcare had 2 more articles in the media than Vyome. MarketBeat recorded 2 mentions for Sensus Healthcare and 0 mentions for Vyome. Vyome's average media sentiment score of 0.00 beat Sensus Healthcare's score of -0.08 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Neutral
Sensus Healthcare	Neutral

Sensus Healthcare has higher revenue and earnings than Vyome. Sensus Healthcare is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A

Vyome has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

22.1% of Vyome shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sensus Healthcare has a net margin of -34.50% compared to Vyome's net margin of -270.58%. Sensus Healthcare's return on equity of -15.79% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-203.92%	-134.16%
Sensus Healthcare	-34.50%	-15.79%	-14.02%

Vyome currently has a consensus price target of $15.00, suggesting a potential upside of 572.65%. Sensus Healthcare has a consensus price target of $6.88, suggesting a potential upside of 115.52%. Given Vyome's higher probable upside, equities research analysts plainly believe Vyome is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Sensus Healthcare beats Vyome on 10 of the 16 factors compared between the two stocks.

How does Vyome compare to electroCore?

electroCore (NASDAQ:ECOR) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

electroCore presently has a consensus target price of $18.00, suggesting a potential upside of 169.87%. Vyome has a consensus target price of $15.00, suggesting a potential upside of 572.65%. Given Vyome's stronger consensus rating and higher possible upside, analysts clearly believe Vyome is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vyome has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.73	-$13.97M	-$1.77	N/A
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A

electroCore has a net margin of -44.08% compared to Vyome's net margin of -270.58%. Vyome's return on equity of -203.92% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Vyome	-270.58%	-203.92%	-134.16%

electroCore has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Vyome has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

26.7% of electroCore shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 13.8% of electroCore shares are held by company insiders. Comparatively, 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, electroCore had 3 more articles in the media than Vyome. MarketBeat recorded 3 mentions for electroCore and 0 mentions for Vyome. electroCore's average media sentiment score of 0.69 beat Vyome's score of 0.00 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Positive
Vyome	Neutral

Summary

Vyome beats electroCore on 9 of the 16 factors compared between the two stocks.

How does Vyome compare to InspireMD?

Vyome (NASDAQ:HIND) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Vyome has a net margin of -270.58% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-203.92%	-134.16%
InspireMD	-413.96%	-69.42%	-57.68%

Vyome presently has a consensus target price of $15.00, indicating a potential upside of 572.65%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 350.00%. Given Vyome's higher possible upside, equities research analysts plainly believe Vyome is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, InspireMD had 16 more articles in the media than Vyome. MarketBeat recorded 16 mentions for InspireMD and 0 mentions for Vyome. Vyome's average media sentiment score of 0.00 beat InspireMD's score of -0.69 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Neutral
InspireMD	Negative

22.1% of Vyome shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 34.1% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vyome has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Vyome has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A
InspireMD	$10.85M	4.32	-$19.92M	-$0.73	N/A

Summary

InspireMD beats Vyome on 8 of the 15 factors compared between the two stocks.

How does Vyome compare to Nutriband?

Vyome (NASDAQ:HIND) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Vyome's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Company	Overall Sentiment
Vyome	Neutral
Nutriband	Neutral

Nutriband has higher revenue and earnings than Vyome. Nutriband is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A
Nutriband	$2.04M	21.70	-$8.23M	-$2.60	N/A

Vyome presently has a consensus price target of $15.00, indicating a potential upside of 572.65%. Given Vyome's stronger consensus rating and higher possible upside, analysts clearly believe Vyome is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

22.1% of Vyome shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vyome has a net margin of -270.58% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-203.92%	-134.16%
Nutriband	-403.98%	-118.33%	-101.92%

Vyome has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Summary

Vyome and Nutriband tied by winning 7 of the 14 factors compared between the two stocks.

How does Vyome compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Plus Therapeutics had 3 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Plus Therapeutics and 0 mentions for Vyome. Plus Therapeutics' average media sentiment score of 0.19 beat Vyome's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Vyome	Neutral

Vyome has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	8.70	-$22.39M	-$2.30	N/A
Vyome	$320K	48.92	-$10.26M	-$12.27	N/A

Plus Therapeutics presently has a consensus target price of $58.00, suggesting a potential upside of 780.12%. Vyome has a consensus target price of $15.00, suggesting a potential upside of 572.65%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Plus Therapeutics is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Plus Therapeutics has a net margin of -230.24% compared to Vyome's net margin of -270.58%. Plus Therapeutics' return on equity of -198.48% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Vyome	-270.58%	-203.92%	-134.16%

Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Vyome has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Summary

Plus Therapeutics beats Vyome on 11 of the 16 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$15.65M	$3.22B	$4.26B	$12.34B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	-0.18	2.51	21.90	25.66
Price / Sales	48.92	455.93	180.59	86.31
Price / Cash	N/A	3.94	55.68	56.67
Price / Book	1.94	3.20	34.85	7.14
Net Income	-$10.26M	-$76.79M	$112.32M	$335.98M
7 Day Performance	10.95%	1.67%	3.54%	4.11%
1 Month Performance	0.90%	-2.02%	3.58%	2.52%
1 Year Performance	N/A	100.00%	15.80%	35.04%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	2.1948 of 5 stars	$2.23 flat	$15.00 +572.6%	N/A	$15.65M	$320K	N/A	50	Gap Down
SRTS Sensus Healthcare	3.3257 of 5 stars	$3.32 -0.9%	$6.88 +107.1%	-32.0%	$55.15M	$27.48M	N/A	40
ECOR electroCore	2.7461 of 5 stars	$6.13 +3.7%	$18.00 +193.6%	+34.2%	$48.99M	$32.03M	N/A	50
NSPR InspireMD	3.6117 of 5 stars	$1.00 flat	$4.50 +350.0%	-60.5%	$46.84M	$10.85M	N/A	50	Positive News
NTRB Nutriband	0.2217 of 5 stars	$3.53 +2.3%	N/A	-33.6%	$41.94M	$2.04M	N/A	10	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors

HIND vs. SRTS, ECOR, NSPR, NTRB, and PSTV

How does Vyome compare to Sensus Healthcare?

Summary

How does Vyome compare to electroCore?

Summary

How does Vyome compare to InspireMD?

Summary

How does Vyome compare to Nutriband?

Summary

How does Vyome compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vyome (HIND) Competitors

HIND vs. SRTS, ECOR, NSPR, NTRB, and PSTV

How does Vyome compare to Sensus Healthcare?

Does the media favor HIND or SRTS?

Which has preferable valuation & earnings, HIND or SRTS?

Which has more risk & volatility, HIND or SRTS?

Do insiders and institutionals have more ownership in HIND or SRTS?

Is HIND or SRTS more profitable?

Do analysts rate HIND or SRTS?

Summary

How does Vyome compare to electroCore?

Do analysts rate ECOR or HIND?

Which has better valuation and earnings, ECOR or HIND?

Is ECOR or HIND more profitable?

Which has more risk and volatility, ECOR or HIND?

Do institutionals and insiders have more ownership in ECOR or HIND?

Does the media refer more to ECOR or HIND?

Summary

How does Vyome compare to InspireMD?

Is HIND or NSPR more profitable?

Do analysts rate HIND or NSPR?

Does the media prefer HIND or NSPR?

Do institutionals and insiders believe in HIND or NSPR?

Which has more volatility and risk, HIND or NSPR?

Which has preferable earnings and valuation, HIND or NSPR?

Summary

How does Vyome compare to Nutriband?

Does the media favor HIND or NTRB?

Which has higher earnings & valuation, HIND or NTRB?

Do analysts prefer HIND or NTRB?

Do institutionals & insiders hold more shares of HIND or NTRB?

Is HIND or NTRB more profitable?

Which has more volatility and risk, HIND or NTRB?

Summary

How does Vyome compare to Plus Therapeutics?

Does the media refer more to PSTV or HIND?

Which has preferable valuation & earnings, PSTV or HIND?

Do analysts recommend PSTV or HIND?

Do insiders & institutionals have more ownership in PSTV or HIND?

Is PSTV or HIND more profitable?

Which has more volatility & risk, PSTV or HIND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools